pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein
暂无分享,去创建一个
Li Li | Yuk Yin Sham | Y. Sham | Z. Bikádi | W. Elmquist | William F Elmquist | Zsolt Bikadi | Li Li
[1] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Schinkel,et al. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.
[3] N. Shaik,et al. Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design , 2009, Drug Metabolism and Disposition.
[4] John D. Allen,et al. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. , 2002, Cancer research.
[5] I. Goldman,et al. The molecular identity and characterization of a Proton-Coupled Folate Transporter—PCFT; biological ramifications and impact on the activity of pemetrexed—12 06 06 , 2007, Cancer and Metastasis Reviews.
[6] A. Fiser,et al. The Functional Roles of the His247 and His281 Residues in Folate and Proton Translocation Mediated by the Human Proton-coupled Folate Transporter SLC46A1* , 2009, The Journal of Biological Chemistry.
[7] G. Peters,et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. , 2005, Cancer research.
[8] Peter Vaupel,et al. Tumor microenvironmental physiology and its implications for radiation oncology. , 2004, Seminars in radiation oncology.
[9] W. El-Deiry. Phenomenology and Scientific Progress , 2002, Cancer biology & therapy.
[10] Xiaokun Cai,et al. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport. , 2010, American journal of physiology. Cell physiology.
[11] Daxi Sun,et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. , 2007, Cancer research.
[12] W. C. Still,et al. Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .
[13] T. Taira,et al. The extracellular pH dependency of transport activity by human oligopeptide transporter 1 (hPEPT1) expressed stably in Chinese hamster ovary (CHO) cells: a reason for the bell-shaped activity versus pH. , 2006, Biological & pharmaceutical bulletin.
[14] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[15] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[16] S. Bates,et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.
[17] B. Noszál,et al. Determination of dissociation constants of folic acid, methotrexate, and other photolabile pteridines by pressure‐assisted capillary electrophoresis , 2006, Electrophoresis.
[18] T. Litman,et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] G. Capellá,et al. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. , 2003, The Journal of urology.
[20] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[21] K. Giacomini,et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. , 2006, Journal of pharmaceutical sciences.
[22] R. Ford,et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. , 2010, Structure.
[23] Honggang Wang,et al. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. , 2008, Biochemistry.
[24] I. Tannock,et al. Acid pH in tumors and its potential for therapeutic exploitation. , 1989, Cancer research.
[25] Jos H. Beijnen,et al. The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models , 2007, Molecular Pharmacology.
[26] György M. Keserű,et al. Comparative Evaluation of in Silico pKa Prediction Tools on the Gold Standard Dataset , 2009 .
[27] E. L. Volk,et al. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.
[28] R. Callaghan,et al. Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter , 2006, British journal of pharmacology.
[29] J. Nezu,et al. Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human , 2004, Journal of Pharmacology and Experimental Therapeutics.
[30] Ulf Norinder,et al. A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.
[31] J. Griffiths,et al. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous 19F and 31P probes , 1999, NMR in biomedicine.
[32] T. Litman,et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.
[33] V. Ganapathy,et al. Identification of the histidyl residue obligatory for the catalytic activity of the human H+/peptide cotransporters PEPT1 and PEPT2. , 1997, Biochemistry.
[34] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[35] T. Litman,et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. , 2006, Cancer letters.
[36] S. Masuda,et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.
[37] A. Dantzig,et al. A high-throughput assay for measurement of multidrug resistance protein-mediated transport of leukotriene C4 into membrane vesicles. , 2002, Analytical biochemistry.
[38] Yehuda G. Assaraf,et al. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates , 2006, Cancer Chemotherapy and Pharmacology.
[39] A. Dantzig,et al. Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.